title: Cutaneous sarcoidosis therapy updated.
abstract: The widely accepted standard therapy for cutaneous sarcoidosis includes corticosteroids, antimalarials, and methotrexate. However, a better understanding of the basic immunopathogenic properties of sarcoidosis has elucidated a number of steps critical to the persistence and progression of disease that may be vulnerable to treatment by targeted therapy. This article reviews both standard and newer therapeutic options for cutaneous sarcoidosis.
authors.affiliation: Dermatology Department, Baylor College of Medicine, and Houston Veterans Affairs Medical Center, Texas, USA.
authors.forename: Christy
authors.initials: C
authors.lastname: Badgwell
authors.forename: Ted
authors.initials: T
authors.lastname: Rosen
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000517:prevention & control; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000493:Allopurinol / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D017951:Antigen Presentation / Q000187:drug effects; D000962:Antimalarials / Q000627:therapeutic use; D002699:Chlorambucil / Q000627:therapeutic use; D000075202:Contraindications; D016572:Cyclosporine / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D003879:Dermatologic Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D007555:Isoxazoles / Q000627:therapeutic use; D053685:Laser Therapy; D000077339:Leflunomide; D008297:Male; D008550:Melatonin / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D018448:Models, Immunological; D010431:Pentoxifylline / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000276:immunology; D012507:Sarcoidosis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D012871:Skin Diseases / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology / Q000473:pathology; D013754:Tetracyclines / Q000627:therapeutic use; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology; D013792:Thalidomide / Q000627:therapeutic use
chemical_list: D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000962:Antimalarials; D016207:Cytokines; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D013754:Tetracyclines; D002699:Chlorambucil; D013792:Thalidomide; D000493:Allopurinol; D016572:Cyclosporine; D000069285:Infliximab; D000077339:Leflunomide; D008550:Melatonin; D010431:Pentoxifylline; D008727:Methotrexate